Introduction: This study evaluated objective response and safety for the combination of granulocyte macrophage-colony stimulating factor (GM-CSF), ketoconazole, and mitoxantrone in castration-resistant prostate cancer (CRPC) patients who previously failed docetaxel-based chemotherapy.
Methods: Treatment consisted of 400 mg TID ketoconazole, 12 mg/m2 mitoxantrone every 3 weeks, and 250 μg/m2 GM-CSF.
Results: Twenty-nine patients were evaluable for response. Median overall survival (OS) for all patients was 18.03 months. Patients with a higher PSA decrease experienced an increased OS and progression-free survival (PFS).
Conclusion: This combination demonstrated significant antitumor activity with reversible toxicity in CRPC patients who previously failed docetaxel-based therapy.
Written by:
Amato RJ, Saxena S, Stepankiw M. Are you the author?
The University of Texas Health Science Center at Houston, Department of Internal Medicine, Division of Oncology, Houston, Texas, USA.
Reference: Cancer Invest. 2013 Mar;31(3):177-82.
doi: 10.3109/07357907.2013.764564
PubMed Abstract
PMID: 23402284
Go "Beyond the Abstract" - Read an Article Written by the Authors for UroToday.com
